Short Interest in LENSAR, Inc. (NASDAQ:LNSR) Drops By 22.6%

LENSAR, Inc. (NASDAQ:LNSR) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 49,800 shares, a drop of 22.6% from the October 15th total of 64,300 shares. Based on an average daily volume of 31,200 shares, the short-interest ratio is currently 1.6 days. Approximately 0.6% of the shares of the stock are sold short.

LENSAR Price Performance

LNSR stock traded down $0.12 during mid-day trading on Friday, hitting $7.08. 33,734 shares of the stock were exchanged, compared to its average volume of 42,733. The stock has a market capitalization of $82.20 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. The business has a fifty day moving average price of $5.28 and a 200 day moving average price of $4.75. LENSAR has a 12 month low of $2.10 and a 12 month high of $7.95.

Institutional Investors Weigh In On LENSAR

A number of institutional investors have recently made changes to their positions in LNSR. Sanctuary Advisors LLC purchased a new position in LENSAR in the 2nd quarter worth approximately $93,000. Geode Capital Management LLC grew its holdings in LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after acquiring an additional 3,423 shares during the last quarter. DCF Advisers LLC increased its position in shares of LENSAR by 1.4% in the second quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock valued at $1,087,000 after acquiring an additional 3,250 shares during the period. Finally, Brandes Investment Partners LP grew its stake in shares of LENSAR by 12.8% in the second quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock worth $1,644,000 after purchasing an additional 42,250 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.